Table S5 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies

Valsasina, Barbara; Orsini, Paolo; Caruso, Michele; Albanese, Clara; Ciavolella, Antonella; Cucchi, Ulisse; Fraietta, Ivan; Melillo, Nicola; Fiorentini, Francesco; Rizzi, Simona; Salsa, Matteo; Isacchi, Antonella; Gasparri, Fabio

doi:10.1158/1535-7163.24710083.v1

mct-23-0315_table_s5_suppst5.docx (19.77 kB)

Table S5 from Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies

journal contribution

posted on 2023-12-01, 07:43 authored by Barbara Valsasina, Paolo Orsini, Michele Caruso, Clara Albanese, Antonella Ciavolella, Ulisse Cucchi, Ivan Fraietta, Nicola Melillo, Francesco Fiorentini, Simona Rizzi, Matteo Salsa, Antonella Isacchi, Fabio Gasparri

NMS-P945 stability in plasma

Funding

n/a

History

ARTICLE ABSTRACT

New antibodies–drug conjugate (ADC) payloads overcoming chemoresistance and killing also poorly proliferating tumors at well-tolerated doses are much desired. Duocarmycins are a well-known class of highly potent cytotoxic agents, with DNA minor groove-binding and alkylation properties, active also in chemoresistant tumors. Although different duocarmycin derivatives have been used during the years as payloads for ADC production, unfavorable physicochemical properties impaired the production of ADCs with optimal features. Optimization of the toxin to balance reactivity and stability features and best linker selection allowed us to develop the novel duocarmycin-like payload–linker NMS-P945 suitable for conjugation to mAbs with reproducible drug–antibody ratio (DAR) >3.5. When conjugated to trastuzumab, it generated an ADC with good internalization properties, ability to induce bystander effect and immunogenic cell death. Moreover, it showed strong target-driven activity in cells and cytotoxic activity superior to trastuzumab deruxtecan tested, in parallel, in cell lines with HER2 expression. High in vivo efficacy with cured mice at well-tolerated doses in HER2-driven models was also observed. A developed pharmacokinetic/pharmacodynamic (PK/PD) model based on efficacy in mice and cynomolgus monkey PK data, predicted tumor regression in patients upon administration of 2 doses of trastuzumab–NMS-P945–ADC at 0.5 mg/kg. Thus, considering the superior physicochemical features for ADC production and preclinical results obtained with the model trastuzumab ADC, including bystander effect, immunogenic cell death and activity in chemoresistant tumors, NMS-P945 represents a highly effective, innovative payload for the creation of novel, next-generation ADCs.